Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...

Scilex宣佈與FDA成功舉行了第二階段會議的結束，達成一致前進到新藥申請(NDA)的路徑，完成第三階段試驗，用於治療...

Benzinga · 10/30 18:20

Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of Chronic Neck Pain Associated With Muscle Spasms

Scilex宣佈與FDA成功舉行了第二階段會議的結束，達成一致前進到新藥申請(NDA)的路徑，完成第三階段試驗，用於治療慢性頸部疼痛伴隨肌肉痙攣的爆款產品候選SP-103(利多卡因局部系統) 5.4%

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。